Are HCTZ-Containing Products Associated With Increased Risk of Non-Melanoma Skin Cancers?

Research & Scholarship: Non-textual formWeb publication/site

Abstract

Recent studies have found an elevated risk of non-melanoma skin cancer associated with hydrochlorothiazide (HCTZ)-containing products due to its photosensitizing properties. Efe Eworuke, PhD, and colleagues at the Center for Drug Evaluation and Research, U.S. Food and Drug Administration, determined that among White individuals, there appears to be a “small” increased risk of both basal cell and squamous cell carcinomas with the use of HCTZ compared with angiotensin-converting enzyme (ACE) inhibitors. The results of their study were published in JNCI Cancer Spectrum. 
Original languageAmerican English
StatePublished - Apr 7 2021

Disciplines

  • Life Sciences
  • Medicine and Health Sciences

Cite this